Eli Lilly cedes China breast cancer drug rights to Innovent amid generic pressure
LLY sits 97% above its 52-week low of $623.78.
Summary
Eli Lilly has transferred the commercialization rights for its breast cancer drug Verzenios in mainland China to Innovent Biologics. This strategic move comes as the drug faces increasing generic competition in the Chinese market. While Lilly will continue manufacturing and developing the drug, the transfer allows Innovent to manage local sales. This defensive adjustment for an existing drug contrasts with Lilly's recent string of positive news regarding new blockbuster drugs like Foundayo, Mounjaro, and Zepbound. The financial terms of the agreement were not disclosed.
At the time of this announcement, LLY was trading at $1,227.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.2T. The 52-week trading range was $623.78 to $1,238.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.